86 related articles for article (PubMed ID: 16110042)
1. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting.
Weber F; Fukino K; Villalona-Calero M; Eng C
J Clin Oncol; 2005 Aug; 23(24):5847-8; author reply 5848-9. PubMed ID: 16110042
[No Abstract] [Full Text] [Related]
2. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
[TBL] [Abstract][Full Text] [Related]
3. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
Saiyaros K; Kritpetcharat P; Pairojkul C; Sithithaworn J
Asian Pac J Cancer Prev; 2019 May; 20(5):1339-1343. PubMed ID: 31127887
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
[TBL] [Abstract][Full Text] [Related]
5. Targeting targeted therapy.
Green MR
N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
[No Abstract] [Full Text] [Related]
6. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
7. [Detection of epidermal growth factor receptor gene mutations and its clinical significance in non-small cell lung cancers].
Zhao J; Zhu Y; Zhang L; Yu YW; Zheng JM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):671-4. PubMed ID: 22321545
[TBL] [Abstract][Full Text] [Related]
8. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
[TBL] [Abstract][Full Text] [Related]
11. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.
Tomonaga N; Nakamura Y; Yamaguchi H; Ikeda T; Mizoguchi K; Motoshima K; Doi S; Nakatomi K; Iida T; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2013 Sep; 14(5):521-6. PubMed ID: 23786997
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutations in lung cancer: the "mysterious mutation".
Hirsch FR
Clin Lung Cancer; 2006 Jul; 8(1):11-2. PubMed ID: 16870039
[No Abstract] [Full Text] [Related]
13. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma.
Matsumoto S; Iwakawa R; Kohno T; Suzuki K; Matsuno Y; Yamamoto S; Noguchi M; Shimizu E; Yokota J
Int J Cancer; 2006 May; 118(10):2498-504. PubMed ID: 16353158
[TBL] [Abstract][Full Text] [Related]
14. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
[TBL] [Abstract][Full Text] [Related]
16. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
[TBL] [Abstract][Full Text] [Related]
17. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
18. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
Hsieh RK; Lim KH; Kuo HT; Tzen CY; Huang MJ
Chest; 2005 Jul; 128(1):317-21. PubMed ID: 16002952
[TBL] [Abstract][Full Text] [Related]
19. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]